CL2019001871A1 - Pautas posológicas y formas farmacéuticas para inhibición de tgf-b selectiva. - Google Patents
Pautas posológicas y formas farmacéuticas para inhibición de tgf-b selectiva.Info
- Publication number
- CL2019001871A1 CL2019001871A1 CL2019001871A CL2019001871A CL2019001871A1 CL 2019001871 A1 CL2019001871 A1 CL 2019001871A1 CL 2019001871 A CL2019001871 A CL 2019001871A CL 2019001871 A CL2019001871 A CL 2019001871A CL 2019001871 A1 CL2019001871 A1 CL 2019001871A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical forms
- inhibition
- dosage guidelines
- selective tgf
- guidelines
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 230000001588 bifunctional effect Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Endoscopes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443698P | 2017-01-07 | 2017-01-07 | |
| US201762581978P | 2017-11-06 | 2017-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001871A1 true CL2019001871A1 (es) | 2019-12-13 |
Family
ID=62791283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001871A CL2019001871A1 (es) | 2017-01-07 | 2019-07-05 | Pautas posológicas y formas farmacéuticas para inhibición de tgf-b selectiva. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190330375A1 (enExample) |
| EP (1) | EP3565599A4 (enExample) |
| JP (1) | JP2020514290A (enExample) |
| KR (1) | KR20190102059A (enExample) |
| CN (1) | CN110198738A (enExample) |
| AU (1) | AU2018205233A1 (enExample) |
| BR (1) | BR112019013924A2 (enExample) |
| CA (1) | CA3048646A1 (enExample) |
| CL (1) | CL2019001871A1 (enExample) |
| IL (1) | IL267856A (enExample) |
| MX (1) | MX2019008001A (enExample) |
| PH (1) | PH12019501574A1 (enExample) |
| RU (1) | RU2019124875A (enExample) |
| SG (1) | SG11201906157YA (enExample) |
| WO (1) | WO2018129331A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| CN116327952A (zh) | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| EP3628049B1 (en) | 2017-05-04 | 2023-05-10 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
| TW202019959A (zh) * | 2018-06-22 | 2020-06-01 | 德商馬克專利公司 | 用於治療膽道癌的標靶性tgf-b抑制之給藥方案 |
| TW202019405A (zh) * | 2018-07-02 | 2020-06-01 | 德商馬克專利公司 | 用於治療晚期非小細胞肺癌之標靶性TGF-β抑制之組合療法 |
| CN120775065A (zh) | 2018-07-09 | 2025-10-14 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| JP7436477B2 (ja) * | 2018-11-09 | 2024-02-21 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | ＴＧＦ－β受容体融合タンパク質医薬組成物およびその使用 |
| MX2021009175A (es) | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos. |
| EP3929215A4 (en) * | 2019-06-10 | 2022-06-22 | Shandong Boan Biotechnology Co., Ltd. | BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGF? AND ITS USE |
| CN112574314A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 一种融合蛋白及其应用 |
| AU2020370370A1 (en) * | 2019-10-24 | 2022-05-05 | Amgen Inc. | Systems and approaches for drug delivery |
| IL292613A (en) * | 2019-11-01 | 2022-07-01 | Ares Trading Sa | Combined inhibition of pd-1, tgfβ and atm together with radiotherapy for the treatment of cancer |
| US20240226235A1 (en) * | 2019-11-05 | 2024-07-11 | Acceleron Pharma Inc. | Treatments for systemic sclerosis |
| EP4073124A4 (en) * | 2019-12-11 | 2024-01-24 | Wuxi Biologics Ireland Limited | BIFUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFBETA |
| KR20220118514A (ko) * | 2019-12-20 | 2022-08-25 | 아레스 트레이딩 에스.아. | IgG:TGF베타RII 융합 단백질 조성물 |
| CN111118064B (zh) * | 2019-12-24 | 2022-10-25 | 华南理工大学 | 一种精子生成障碍动物模型及其制备方法与应用 |
| WO2021142448A2 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock,Inc. | Tgf-beta inhibitors and use thereof |
| TW202135862A (zh) | 2020-01-11 | 2021-10-01 | 美商供石公司 | TGFβ抑制劑及其用途 |
| CN115135675A (zh) * | 2020-02-18 | 2022-09-30 | 南京金斯瑞生物科技有限公司 | 融合蛋白及其用途 |
| CN115175942B (zh) * | 2020-02-25 | 2025-05-30 | 上海药明生物技术有限公司 | 一种双功能融合蛋白及其用途 |
| WO2022011256A1 (en) | 2020-07-10 | 2022-01-13 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| WO2022063193A1 (zh) * | 2020-09-24 | 2022-03-31 | 上海齐鲁制药研究中心有限公司 | 同时靶向PD-L1和TGFβ的双功能分子及其医药用途 |
| CN116981485A (zh) | 2021-03-08 | 2023-10-31 | 南京金斯瑞生物科技有限公司 | 使用双重病毒载体系统递送抗体 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| KR20240101664A (ko) * | 2021-11-19 | 2024-07-02 | 메뤼스 엔.페. | Pd-1 및 tgf-brii 결합 도메인을 포함하는 다중특이성 결합 모이어티 |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785682A (en) * | 1995-03-22 | 1998-07-28 | Abbott Laboratories | Pre-filled syringe drug delivery system |
| IL323000A (en) * | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| US20130110045A1 (en) * | 2011-10-31 | 2013-05-02 | Ming-Yuan Wu | Single use intravenous therapy administering device with needle safety covers |
| ES2938182T3 (es) * | 2012-04-30 | 2023-04-05 | Biocon Ltd | Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| AU2015213988B2 (en) * | 2014-02-10 | 2019-07-11 | Merck Patent Gmbh | Targeted TGFbeta inhibition |
| EP3206711B1 (en) * | 2014-10-14 | 2023-05-31 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| US10828353B2 (en) * | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| EP3277716B1 (en) * | 2015-04-03 | 2020-06-24 | XOMA Technology Ltd. | Treatment of cancer using inhibitors of tgf-beta and pd-1 |
| PT3294770T (pt) * | 2015-05-12 | 2020-12-04 | Hoffmann La Roche | Métodos terapêuticos e diagnósticos para o cancro |
-
2018
- 2018-01-05 RU RU2019124875A patent/RU2019124875A/ru unknown
- 2018-01-05 CA CA3048646A patent/CA3048646A1/en active Pending
- 2018-01-05 EP EP18736497.1A patent/EP3565599A4/en active Pending
- 2018-01-05 CN CN201880006085.0A patent/CN110198738A/zh active Pending
- 2018-01-05 BR BR112019013924-9A patent/BR112019013924A2/pt not_active Application Discontinuation
- 2018-01-05 KR KR1020197022795A patent/KR20190102059A/ko not_active Ceased
- 2018-01-05 MX MX2019008001A patent/MX2019008001A/es unknown
- 2018-01-05 WO PCT/US2018/012604 patent/WO2018129331A1/en not_active Ceased
- 2018-01-05 SG SG11201906157YA patent/SG11201906157YA/en unknown
- 2018-01-05 JP JP2019536228A patent/JP2020514290A/ja active Pending
- 2018-01-05 AU AU2018205233A patent/AU2018205233A1/en not_active Abandoned
-
2019
- 2019-07-02 US US16/460,792 patent/US20190330375A1/en not_active Abandoned
- 2019-07-03 PH PH12019501574A patent/PH12019501574A1/en unknown
- 2019-07-04 IL IL267856A patent/IL267856A/en unknown
- 2019-07-05 CL CL2019001871A patent/CL2019001871A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190330375A1 (en) | 2019-10-31 |
| JP2020514290A (ja) | 2020-05-21 |
| CN110198738A (zh) | 2019-09-03 |
| WO2018129331A1 (en) | 2018-07-12 |
| RU2019124875A3 (enExample) | 2021-07-08 |
| AU2018205233A1 (en) | 2019-07-11 |
| MX2019008001A (es) | 2019-09-09 |
| EP3565599A1 (en) | 2019-11-13 |
| EP3565599A4 (en) | 2020-07-01 |
| SG11201906157YA (en) | 2019-08-27 |
| RU2019124875A (ru) | 2021-02-08 |
| IL267856A (en) | 2019-09-26 |
| KR20190102059A (ko) | 2019-09-02 |
| PH12019501574A1 (en) | 2019-11-04 |
| CA3048646A1 (en) | 2018-07-12 |
| BR112019013924A2 (pt) | 2020-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001871A1 (es) | Pautas posológicas y formas farmacéuticas para inhibición de tgf-b selectiva. | |
| CL2019000979A1 (es) | Composiciones y anticuerpos anti-lag-3. | |
| CL2017003261A1 (es) | Factor xi anticuerpos y métodos de uso | |
| CU20160133A7 (es) | Anticuerpos anti-mcam y métodos de uso asociados | |
| TWD192896S (zh) | 按摩器 | |
| BR112019005908A2 (pt) | uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres | |
| CL2016002017A1 (es) | Inhibición dirigida del factor de crecimiento transformador b (tgfb). | |
| MA53973A (fr) | Inhibiteurs de la réplication du virus de l'immunodéficience humaine | |
| CL2019001996A1 (es) | Usos terapéuticos de un polvo de insectos. | |
| AR103246A1 (es) | Derivados de fgf21 y sus usos | |
| MX2020007527A (es) | Tratamiento de enfermedades oftalmologicas. | |
| GT201800018A (es) | Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana | |
| PE20171076A1 (es) | Composicion que contiene quitina y proteinas digeribles | |
| CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
| MX2018012285A (es) | Metodos de tratamiento para enfermedades colestasicas y fibroticas. | |
| UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| MX2018008640A (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano. | |
| ECSP18060864A (es) | Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| CO2023008676A2 (es) | Compuestos polipéptidos modificados con lactama | |
| SV2016005331A (es) | Derivados de naftiridinadiona | |
| PE20151866A1 (es) | Composiciones nutricionales que contienen un componente peptidico con propiedades estimulantes de adiponectina y usos del mismo | |
| MY208454A (en) | Anti-connective tissue growth factor antibody and application thereof | |
| UY36261A (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| MX2021009413A (es) | Materiales y métodos para tratar una enfermedad neurodegenerativa. |